HUP0302515A2 - Szulfamido-tienopirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Szulfamido-tienopirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0302515A2 HUP0302515A2 HU0302515A HUP0302515A HUP0302515A2 HU P0302515 A2 HUP0302515 A2 HU P0302515A2 HU 0302515 A HU0302515 A HU 0302515A HU P0302515 A HUP0302515 A HU P0302515A HU P0302515 A2 HUP0302515 A2 HU P0302515A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- groups
- compounds
- replaced
- halogen atom
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány (I) általános képletű vegyületekre, sóikra és/vagyszolvátjaikra vonatkozik, ahol a képletben R1 és R2 jelentéseegymástól függetlenül hidrogénatom, OA1, OCOA1, hidroxilcsoport vagyhalogénatom vagy R1 és R2 együtt 3-5 szénatomos alkiléncsoportot, -O-CH2-CH2-, -CH2-O-CH2-, -O-CH2-O- vagy -O-CH2-CH2-O- csoportot jelent,X jelentése -CH2SO2NR3R4 képletű csoport, R3 és R4 jelentése egymástólfüggetlenül hidrogénatom heteroaromás gyök, helyettesítetlen vagy avégcsoporton -NH2, -NHA1 vagy -NA1A2 csoporttal helyettesített 1-10szénatomos alkil- vagy alkenilcsoport, amelyben egy vagy két -CH2-csoport helyett -CH=CH- csoportok, -O-, -NH- vagy -NA1- csoportállhat, vagy R3 és R4 együtt 3-7 szénatomos cikloalkil- vagycikloalkilén- csoportot jelent, mely csoportok lehetnekhelyettesítetlenek vagy halogénatommal, -NH2, -NHA, -NA1A2, -NHCOA1,NHCOOA1, -COOH, -COOA1, -CONH2, -CONHA1 vagy -CONA1A2 csoporttalegyszeresen vagy többszörösen helyettesítettek, és amelyekben egy vagykét -CH2- csoport helyett -O-, -NH-, -NA1-, -NCOA1- vagy -NCOOA1-csoport állhat, A1 és A2 jelentése egymástól függetlenül 1-10szénatomos alkil- vagy alkenilcsoport, amelyek 1-5 fluoratommalés/vagy klóratommal lehetnek helyettesítve, vagy A1 és A2 együtt 3-7szénatomos cikloalkil- vagy cikloalkilén- csoportot jelent, amelyekbenegy -CH2- csoport helyett -O-, -NH-, -NA1-, -NCOA1- vagy -NCOOA1-csoport állhat, és a halogénatom fluor-, klór-, bróm- vagy jódatomlehet. R1, R2 és X jelentése az 1. igénypontban megadottal egyező. Avegyületek elsősorban kardiovaszkuláris megbetegedések éspotenciazavarok kezelésére és megelőzésére használhatók. A találmánykiterjed a vegyületek előállítására és ezeket tartalmazógyógyszerkészítményekre is. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10064994A DE10064994A1 (de) | 2000-12-23 | 2000-12-23 | Sulfamidothienopyrimidine |
| PCT/EP2001/014102 WO2002051848A2 (de) | 2000-12-23 | 2001-12-03 | Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0302515A2 true HUP0302515A2 (hu) | 2003-11-28 |
| HUP0302515A3 HUP0302515A3 (en) | 2005-06-28 |
Family
ID=7668967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302515A HUP0302515A3 (en) | 2000-12-23 | 2001-12-03 | Sulfanidothienopyrimidines, process for their preparation and pharmaceutical compositions containing them |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7019013B2 (hu) |
| EP (1) | EP1353927B1 (hu) |
| JP (1) | JP4550361B2 (hu) |
| KR (1) | KR20030062438A (hu) |
| CN (1) | CN1483035A (hu) |
| AR (1) | AR035524A1 (hu) |
| AT (1) | ATE302781T1 (hu) |
| BR (1) | BR0115996A (hu) |
| CA (1) | CA2432582C (hu) |
| CZ (1) | CZ20031815A3 (hu) |
| DE (2) | DE10064994A1 (hu) |
| ES (1) | ES2247007T3 (hu) |
| HU (1) | HUP0302515A3 (hu) |
| MX (1) | MXPA03005714A (hu) |
| PL (1) | PL361733A1 (hu) |
| RU (1) | RU2003122189A (hu) |
| SK (1) | SK8432003A3 (hu) |
| WO (1) | WO2002051848A2 (hu) |
| ZA (1) | ZA200305659B (hu) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100343258C (zh) * | 2001-04-30 | 2007-10-17 | 美国拜尔公司 | 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物 |
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| EP1874781B9 (de) * | 2006-04-19 | 2010-09-08 | Boehringer Ingelheim International GmbH | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen |
| WO2008088727A2 (en) | 2007-01-12 | 2008-07-24 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| WO2008090114A1 (en) | 2007-01-24 | 2008-07-31 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| NZ585348A (en) | 2007-10-19 | 2012-02-24 | Boehringer Ingelheim Int | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| CA2702518A1 (en) | 2007-10-19 | 2009-04-23 | Boehringer Ingelheim International Gmbh | New piperazino-dihydrothienopyrimidine derivatives |
| CA2705414C (en) | 2007-10-19 | 2016-05-24 | Boehringer Ingelheim International Gmbh | Substituted piperidino-dihydrothienopyrimidines |
| JP6042331B2 (ja) | 2010-07-23 | 2016-12-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | プロテアソーム活性を向上させる三環系化合物 |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| EP2806875B1 (en) | 2012-01-25 | 2017-07-19 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19644228A1 (de) * | 1996-10-24 | 1998-04-30 | Merck Patent Gmbh | Thienopyrimidine |
| DE19752952A1 (de) * | 1997-11-28 | 1999-06-02 | Merck Patent Gmbh | Thienopyrimidine |
| DE19819023A1 (de) * | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
| KR20010105399A (ko) | 1999-03-30 | 2001-11-28 | 쓰끼하시 다미까따 | 티에노피리미딘 화합물 및 그의 염, 및 그들의 제조 방법 |
-
2000
- 2000-12-23 DE DE10064994A patent/DE10064994A1/de not_active Withdrawn
-
2001
- 2001-12-03 AT AT01271992T patent/ATE302781T1/de not_active IP Right Cessation
- 2001-12-03 JP JP2002552942A patent/JP4550361B2/ja not_active Expired - Fee Related
- 2001-12-03 PL PL01361733A patent/PL361733A1/xx unknown
- 2001-12-03 RU RU2003122189/04A patent/RU2003122189A/ru not_active Application Discontinuation
- 2001-12-03 HU HU0302515A patent/HUP0302515A3/hu unknown
- 2001-12-03 DE DE50107230T patent/DE50107230D1/de not_active Expired - Lifetime
- 2001-12-03 SK SK843-2003A patent/SK8432003A3/sk unknown
- 2001-12-03 US US10/451,183 patent/US7019013B2/en not_active Expired - Fee Related
- 2001-12-03 MX MXPA03005714A patent/MXPA03005714A/es not_active Application Discontinuation
- 2001-12-03 CN CNA018212190A patent/CN1483035A/zh active Pending
- 2001-12-03 EP EP01271992A patent/EP1353927B1/de not_active Expired - Lifetime
- 2001-12-03 CZ CZ20031815A patent/CZ20031815A3/cs unknown
- 2001-12-03 KR KR10-2003-7008265A patent/KR20030062438A/ko not_active Application Discontinuation
- 2001-12-03 ES ES01271992T patent/ES2247007T3/es not_active Expired - Lifetime
- 2001-12-03 BR BR0115996-8A patent/BR0115996A/pt not_active Application Discontinuation
- 2001-12-03 CA CA2432582A patent/CA2432582C/en not_active Expired - Fee Related
- 2001-12-03 WO PCT/EP2001/014102 patent/WO2002051848A2/de active IP Right Grant
- 2001-12-19 AR ARP010105889A patent/AR035524A1/es not_active Application Discontinuation
-
2003
- 2003-07-22 ZA ZA200305659A patent/ZA200305659B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004516329A (ja) | 2004-06-03 |
| PL361733A1 (en) | 2004-10-04 |
| AR035524A1 (es) | 2004-06-02 |
| US20040063943A1 (en) | 2004-04-01 |
| ATE302781T1 (de) | 2005-09-15 |
| ZA200305659B (en) | 2004-08-27 |
| CA2432582A1 (en) | 2002-07-04 |
| KR20030062438A (ko) | 2003-07-25 |
| WO2002051848A2 (de) | 2002-07-04 |
| JP4550361B2 (ja) | 2010-09-22 |
| CZ20031815A3 (cs) | 2003-10-15 |
| US7019013B2 (en) | 2006-03-28 |
| HUP0302515A3 (en) | 2005-06-28 |
| RU2003122189A (ru) | 2004-12-27 |
| BR0115996A (pt) | 2004-01-06 |
| EP1353927A2 (de) | 2003-10-22 |
| SK8432003A3 (en) | 2003-10-07 |
| DE50107230D1 (de) | 2005-09-29 |
| WO2002051848A3 (de) | 2002-10-24 |
| CA2432582C (en) | 2011-01-25 |
| DE10064994A1 (de) | 2002-07-04 |
| EP1353927B1 (de) | 2005-08-24 |
| MXPA03005714A (es) | 2003-10-06 |
| CN1483035A (zh) | 2004-03-17 |
| ES2247007T3 (es) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| HUP0302515A2 (hu) | Szulfamido-tienopirimidin-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0302487A2 (hu) | Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0105472A2 (hu) | Lineáris ciklodextrin kopolimerek és eljárás az előállításukra | |
| HUP0100156A2 (hu) | Foszfolipáz-A2 inhibitor hatású indolszármazékok és alkalmazásuk gyógyászati készítmények előállítására | |
| HUP0001555A2 (hu) | Tetrahidro-imidazo-naftiridin származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
| HUP0300434A2 (hu) | Oxazolszármazékok és alkalmazásuk tirozin-kináz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| MA26697A1 (fr) | Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant | |
| HUP0303354A2 (hu) | Gyulladásgátló hatású 6-alfa, 9-alfa-difluor-17-alfa-(2-furanilkarbonil)oxi-11-béta-hidroxi-16-alfa-metil-3-oxo-androst-1,4-dién-17-tiokarbonsav-S-fluormetil-észter, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény | |
| AP2000002016A0 (en) | 2-(Purin-9-yl) Tetrahydrofuran-3,4-diol derivatives. | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| HUP0101999A2 (hu) | 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása | |
| SE0001899D0 (sv) | New compounds | |
| TNSN98203A1 (fr) | Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant | |
| TNSN98084A1 (fr) | Derives de macrolides substitues en position c-4 | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| HUP0100865A2 (hu) | Meta-azaciklusos csoporttal N-szubsztituált amino-benzoesav-vegyületek és származékaik mint integrin antagonista hatóanyagok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| HUP0203422A2 (hu) | Foszfodiészteráz VII inhibitor hatású imidazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| TN2010000025A1 (fr) | Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| MD382C2 (ro) | Procedeu de obţinere a piperazinilalchil-3(2H)-piridazinonelor sau a sărurilor lor farmaceutice admisibile | |
| CY1109950T1 (el) | Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν |